Acompanhe as Notícias da Recifes

The U.S. Food and Drug Administration has approved an expanded indication for Zoryve (roflumilast) cream, 0.3%, for the topical treatment of plaque psoriasis in patients ages 2 and older. The expanded approval was granted to Arcutis Biotherapeutics.

Higher psoriasis (PsO) disease activity is independently associated with impairment in specific sleep domains, but not global sleep quality, according to a study published online May 29 in the Journal of Clinical Medicine.

Biohub researchers have performed what they believe is the first genome-wide CRISPR study of primary human adult skin cells, then used an AI model to mine the results for overlooked drug targets for psoriasis. They found an unlikely candidate: the receptor for oxytocin, a hormone